The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY.
Harding SD, Sharman JL, Faccenda E, Southan C, Pawson AJ, Ireland S, Gray AJG, Bruce L, Alexander SPH, Anderton S, Bryant C, Davenport AP, Doerig C, Fabbro D, Levi-Schaffer F, Spedding M, Davies JA, NC-IUPHAR. · 2018
Read The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. by Harding SD, Sharman JL, Faccenda E, Southan C, Pawson AJ, Ireland S, Gray AJG, Bruce L, Alexander SPH, Anderton S, Bryant C, Davenport AP, Doerig C, Fabbro D, Levi-Schaffer F, Spedding M, Davies JA, NC-IUPHAR. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5753190.txt.
Introduction
Harding and co-authors report the 2018 update of the IUPHAR/BPS Guide to PHARMACOLOGY. This expert checked database logs how drugs and other ligands act on targets. It has grown from work dating back to 2003. Content choice rests with 96 subcommittees of scientists and in-house curators.
The guide now holds about 9,000 ligands and 15,000 binding constants. It links roughly 1,700 human proteins to 6,000 papers. Ten releases since 2015 added content and features. A new sister project, the Guide to IMMUNOPHARMACOLOGY, forks from the same model. It adds immune targets, pathways, cell types, and diseases.
Catalog record
| CREATOR | Harding SD, Sharman JL, Faccenda E, Southan C, Pawson AJ, Ireland S, Gray AJG, Bruce L, Alexander SPH, Anderton S, Bryant C, Davenport AP, Doerig C, Fabbro D, Levi-Schaffer F, Spedding M, Davies JA, NC-IUPHAR. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 61 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY By Simon D Harding, Joanna L Sharman, Elena Faccenda, Chris Southan, Adam J Pawson, Sam Ireland, Alasdair J G Gray, Liam Bruce, Stephen P H Alexander, Stephen Anderton, Clare Bryant, Anthony P Davenport Published in: Nucleic Acids Research DOI: 10.1093/nar/gkx1121 ABSTRACT Abstract The IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb, www.guidetopharmacology.org) and its precursor IUPHAR-DB, have captured expert-curated interactions between targets and ligands from selected papers in pharmacology and drug discovery since 2003. This resource continues to be developed in conjunction with the International Union of Basic and Clinical Pharmacology (IUPHAR) and the British Pharmacological Society (BPS). As previously described, our unique model of content selection and quality control is based on 96 target-class subcommittees comprising 512 scientists collaborating with in-house curators. This update describes content expansion, new features and interoperability improvements introduced in the 10 releases since August 2015. Our relationship matrix now describes ∼9000 ligands, ∼15 000 binding constants, ∼6000 papers and ∼1700 human proteins. As an important addition, we also introduce our newly funded project for the Guide to IMMUNOPHARMACOLOGY (GtoImmuPdb, www.guidetoimmunopharmacology.org). This has been ‘forked’ from the well-established GtoPdb data model and expanded into new types of data related to the immune system and inflammatory processes. This includes new ligands, targets, pathways, cell types and diseases for which we are recruiting new IUPHAR expert committees. Designed as an immunopharmacological gateway, it also has an emphasis on potential therapeutic interventions. INTRODUCTION The International Union of Basic and Clinical Pharmacology/British Pharmacological Society IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb, www.guidetopharmacology.org) is an expert-curated resource of ligand–activity–target relationships, selected from high-quality pharmacological and medicinal chemistry literature. It has its origins in IUPHAR-DB, first compiled in 2003 and focused on receptors and channels (1–3). From 2012 to 2015, the scope expanded to define the data-supported druggable genome and the resource was re-named GtoPdb (4,5). This phase added many new target families and consolidated ligand-to-target relationships for approved drugs and clinical candidates. Over the last 2 years, under the guidance of the IUPHAR Committee on Receptor Nomenclature and Drug Classification (NC-IUPHAR) and its 96 expanded subcommittees (comprising 512 international scientists), we have added quantitative ligand–target relationships showing promise for future drug discovery. We have also enhanced interoperability with other resources and added features to help users access structure-activity relationship (SAR) data and to explore species differences using a new ligand activity visualization tool. From 2015, we have addressed the priority area of immunity, inflammation and infection (6–9). Most chronic diseases, including ageing, have an immune-inflammatory component (10); auto-immunity is a serious problem (11,12), and the progress of infections depends on immune and inflammatory responses (13). There is also increased interest in anti-tumour immune activity, the importance of which is underlined by a new partnership between IUPHAR and the International Union of Immunological Sciences (IUIS) to create standard tools and nomenclature. Critical to facilitate this is a strong connection between the immunity, inflammation and infection research and the pharmacological communities, with easy bidirectional data flow. In particular, pharmacological information is difficult for immunologists to access without chemoinformatic expertise not typically present in immunology labs. Immunology is supported by excellent databases—e.g. ImmPort (www.immport.org), ImmGen (www.immgen.org), InnateDB (www.innatedb.ca/), Reactome (www.reactome.org) and IMGT (www.imgt.org)—but these do not provide easy links to pharmacological data. The development of the ‘IUPHAR Guide to IMMUNOPHARMACOLOGY’ (or GtoImmuPdb for short), with an immunologist-friendly portal, aims to address this gap in information exchange. All data added for the immunopharmacology project are also available from the original GtoPdb site and vice versa. GUIDE TO PHARMACOLOGY CURATION AND EXPANSION The value of the database arises from our approach to document selection, data curation and annotation. Our curation ‘rules’ are better seen as flexible guidelines because expert judgement is exercised at all stages of the process, with the overriding pragmatic principle being to expand content value while maintaining stringency. This quality-centric, ‘small data’ approach contrasts with automated data-mining, large-scale curation operations and ‘big data’ amalgamation efforts. Curation includes checking and fixing author errors (e.g. μM versus nM), adding PubChem cross-pointers between unresolved stereoisomers to the appropriate stable R and S forms, and splitting salts and parents for cheminformatic consistency while also cross-pointing to reported salt forms (e.g. specified by the United States Adopted Names (USAN) or Food and Drug Administration (FDA) drug information sheet). We have recently simplified the representation of activity ranges to one-value-one-reference relationships, extending this principle for patent-only entries and adapting legacy data to this form. Content Targets A ‘target’ record in our database resolves to a UniProtKB/SwissProt Accession as its primary identifier. Since our 2016 publication (5), target expansion has been mainly for GtoImmuPdb. Specifically-added immunity, inflammation and infection targets include the following the pattern recognition receptors/proteins of the innate immune response: RIG-I-like receptor family (www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=940)Absent in melanoma-like receptors (www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=942)C-type lectin-like receptors (www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=945)Other pattern recognition receptors (www.guidetoimmunopharmacology.org/GRAC/FamilyDisplayForward?familyId=929) Immune checkpoint protein targets have been expanded and aggregated in new families, for example Immune checkpoint catalytic receptors (www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=953) and ‘Other immune checkpoint proteins’ (www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=949). This allows us to capture the action of these proteins as both immune system regulators and as drug targets. Another new target family is Butyrophilin and butyrophilin-like proteins were added for their increasingly indicated roles in gamma-delta T cells (14). As part of our ongoing updates of the GtoPdb, we have added other, non-immune targets, including the aryl hydrocarbon receptor and Piezo channels. Our targets are organized into several classes (Table 1A), accessible through the website, each divided into families and subfamilies (Figure 1). Classifications can overlap, for example ‘Immune checkpoint proteins’ are in both the ‘Catalytic receptor’ and the ‘Other protein target’ classes. Joining these different target types is useful to immunologists, given the proteins’ shared roles in regulating T cells and macrophages. [Figure: The hierarchical listing for the catalytic receptor families and subfamilies. (A) Shows the GtoPdb view and (B) shows it with the Guide to IMMUNOPHARMACOLOGY (GtoImmuPdb) view switched on, which highlights families containing targets of immunological relevance. A toggle button enables switching between GtoPdb and GtoImmuPdb views, the only difference being that the GtoPdb view does not have highlighting.] [Table: Guide to PHARMACOLOGY database counts for targets, ligands and interactions from database release 2017.5] Ligands Criteria for including a ligand remain focused on well-characterized, quantitative interactions with protein targets (Table 1B). Of the 816 ligands tagged as having relevance to immunopharmacology (see GtoImmuPdb Expansion-‘Content and curation’ section for details), ∼30% have been added since the last update. As previously, ligands without an experimentally-verified molecular mechanism of action, but where potential efficacy is clearly described in papers, are also captured. There are new ligand groups, for example Immune checkpoint modulators (www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=969), which group disparate ligands with common functionality. We have extended the database schema to group some ligands into families using the information on Hugo Gene Nomenclature Committee (HGNC) gene family pages (www.genenames.org/cgi-bin/genefamilies/) (15,16); examples include cytokines and chemokines. A new family listing page exists under the ‘Ligands’ sub menu of the main navigation bar and also from the ligand list and individual ligand pages (www.guidetopharmacology.org/GRAC/LigandFamiliesForward). Interactions and database growth Table 1C and Figure 2 show the expansion of curated interaction data across targets and ligands. Most targets added over the past